LAVAL, QUEBEC, Jan. 31 /CNW Telbec/ - Genomics One Corporation (“Genomics One”) (TSX: GNX) announced today that the Corporation has signed a letter of intent to purchase patents from Valorisation-Recherche, a limited partnership, for the development of Mass Spectrometry equipment using the Metastable Atoms Bombardment (MAB) Technology. The Corporation will pay a sum of $350,000 CAN and 40,000 common shares of its capital stock for the patents, which will be used in the development and the manufacture of high-end Mass Spectrometry equipment.
